Companies › HUYABIO International
4 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 2, 1 Phase 3; Oncology, Cardiovascular; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HBI-8000 Histone deacetylase inhibitor | HDAC | Phase 3 | Unresectable or Metastatic Melanoma | Dec 2026 |
| HBI-3000 Multi-ion channel blocker | – | Phase 2 | Atrial Fibrillation | – |
| HBI-2376 SHP2 inhibitor | PTPN11 | Phase 1 | Non Small Cell Lung Cancer | Dec 2026 |
| HBI-2438 KRAS G12C inhibitor | KRAS | Phase 1 | Lung Cancer | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04680026 | HBI-3000 | Phase 2 | Atrial Fibrillation | Cardiovascular | Dec 2025 |
| NCT04674683 | HBI-8000 | Phase 3 | Unresectable or Metastatic Melanoma | Oncology | Dec 2026 |
| NCT05163028 | HBI-2376 | Phase 1 | Non Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT05485974 | HBI-2438 | Phase 1 | Lung Cancer | Oncology | Dec 2026 |
Allist Pharmaceuticals BeBetter Med Blueprint Medicines Genfleet Therapeutics (Shanghai) CStone Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.